Association between predicted Skeletal Muscle Index (pSMI) and Benign Prostatic Hyperplasia (BPH) among Chinese Middle-aged and Older Men: Evidence from the CHARLS Study

Shao S1, Xu Z2, Liu W2, Liu X3, Gao C2, Fan M2, Wen Y4, Wen J4

Research Type

Clinical

Abstract Category

Male Lower Urinary Tract Symptoms (LUTS) / Voiding Dysfunction

Abstract 687
Open Discussion ePosters
Scientific Open Discussion Session 107
Friday 9th October 2026
10:35 - 10:40 (ePoster Station 1)
Exhibition Hall
Benign Prostatic Hyperplasia (BPH) Gerontology Male
1. Department of Pediatric Surgery & Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang 453100, China, 2. Department of Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang 453100, China, 3. Department of Gynecology, Xinyang Central Hospital, Xinyang 464000, China, 4. Henan Joint International Paediatric Urodynamic Laboratory, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Presenter
J

Jianguo Wen
Henan Joint International Paediatric Urodynamic Laboratory, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Links

Abstract

Hypothesis / aims of study
Predicted skeletal muscle index (pSMI) is a surrogate marker of skeletal muscle mass, but its relationship with benign prostatic hyperplasia (BPH) remains unclear. This study examined the association between pSMI and the prevalence of BPH in Chinese middle-aged and older men.
Study design, materials and methods
We analyzed 2,424 men aged ≥45 years from the China Health and Retirement Longitudinal Study (CHARLS). pSMI was calculated using a validated equation based on age, anthropometrics, and creatinine–cystatin C, and was evaluated as a continuous variable and by quartiles. BPH was defined by self-reported physician diagnosis. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for BPH in relation to pSMI, adjusting for sociodemographic factors, lifestyle, body mass index, and major cardiometabolic comorbidities. Restricted cubic spline models assessed dose–response patterns, and subgroup analyses explored potential heterogeneity of the association.
Results
We analyzed 2,424 men aged ≥45 years from the China Health and Retirement Longitudinal Study (CHARLS). pSMI was calculated using a validated equation based on age, anthropometrics, and creatinine–cystatin C, and was evaluated as a continuous variable and by quartiles. BPH was defined by self-reported physician diagnosis. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for BPH in relation to pSMI, adjusting for sociodemographic factors, lifestyle, body mass index, and major cardiometabolic comorbidities. Restricted cubic spline models assessed dose–response patterns, and subgroup analyses explored potential heterogeneity of the association.
Interpretation of results
We analyzed 2,424 men aged ≥45 years from the China Health and Retirement Longitudinal Study (CHARLS). pSMI was calculated using a validated equation based on age, anthropometrics, and creatinine–cystatin C, and was evaluated as a continuous variable and by quartiles. BPH was defined by self-reported physician diagnosis. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for BPH in relation to pSMI, adjusting for sociodemographic factors, lifestyle, body mass index, and major cardiometabolic comorbidities. Restricted cubic spline models assessed dose–response patterns, and subgroup analyses explored potential heterogeneity of the association.
Concluding message
Higher pSMI was associated with a higher prevalence of BPH in this population. However, given the observational design and potential residual confounding, these findings should be interpreted as hypothesis-generating. Further prospective studies are needed to clarify the temporal relationship and potential clinical relevance of this association.
Figure 1
Disclosures
Funding This work was supported by the National Natural Science Foundation of China (82470807) Clinical Trial No Subjects Human Ethics Committee Ethical approval for all waves of the CHARLS study was obtained from the Institutional Review Board (IRB) at Peking University. The IRB approval number is IRB00001052-11015. and all participants provided written informed consent. Helsinki Yes Informed Consent Yes AI For simple textual assistance in writing the abstract manuscript
07/06/2026 04:01:38